{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:24:15Z","timestamp":1794007455821,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The neuropathological confirmation of amyloid-\u03b2 (A\u03b2) plaques and tau neurofibrillary tangles (NFT) remains the gold standard for a definitive diagnosis of Alzheimer\u2019s disease (AD). Nowadays, the in vivo diagnosis of AD is greatly aided by both cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers. Although highly accurate, their broad implementation is restricted by high cost, limited accessibility and invasiveness. We recently developed a high-performance, ultrasensitive immunoassay for the quantification of tau phosphorylated at threonine-181 (p-tau181) in plasma, which identifies AD pathophysiology with high accuracy. However, it remains unclear whether plasma p-tau181, measured years before the death, can predict the eventual neuropathological confirmation of AD, and successfully discriminates AD from non-AD dementia pathologies. We studied a unique cohort of 115 individuals with longitudinal blood collections with clinical evaluation at 8, 4 and 2\u00a0years prior to neuropathological assessment at death. The results demonstrate that plasma p-tau181 associates better with AD neuropathology and Braak staging than a clinical diagnosis 8\u00a0years before post-mortem. Moreover, while all patients had a diagnosis of AD dementia during life, plasma p-tau181 proved to discriminate AD from non-AD pathologies with high accuracy (AUC\u2009=\u200997.4%, 95% CI\u2009=\u200994.1\u2013100%) even 8\u00a0years before death. Additionally, the longitudinal trajectory of plasma p-tau181 was assessed in all patients. We found that the main increases in plasma p-tau181 occurred between 8 and 4\u00a0years prior to death in patients with AD neuropathology and later plateauing. In contrast, non-AD pathologies and controls exhibited minor, albeit significant, increases in p-tau181 up until death. Overall, our study demonstrates that plasma p-tau181 is highly predictive and specific of AD neuropathology years before post-mortem examination. These data add further support for the use of plasma p-tau181 to aid clinical management in primary care and recruitment for clinical trials.<\/jats:p>","DOI":"10.1007\/s00401-020-02195-x","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T11:02:42Z","timestamp":1595847762000},"page":"267-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":325,"title":["Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8\u00a0years prior to post-mortem and improves the clinical characterisation of cognitive decline"],"prefix":"10.1007","volume":"140","author":[{"given":"Juan","family":"Lantero Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Su\u00e1rez-Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Troakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreja","family":"Emersic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Hye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6353-9316","authenticated-orcid":false,"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"key":"2195_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41582-020-0348-0","volume":"16","author":"NJ Ashton","year":"2020","unstructured":"Ashton NJ, Hye A, Rajkumar AP, Leuzy A, Snowden S, Suarez-Calvet M et al (2020) An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat Rev Neurol 16:265\u2013284. https:\/\/doi.org\/10.1038\/s41582-020-0348-0","journal-title":"Nat Rev Neurol"},{"key":"2195_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40478-018-0649-3","volume":"7","author":"NJ Ashton","year":"2019","unstructured":"Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortobagyi T, Hoglund K et al (2019) Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun 7:5. https:\/\/doi.org\/10.1186\/s40478-018-0649-3","journal-title":"Acta Neuropathol Commun"},{"key":"2195_CR3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2217\/bmm-2017-0433","volume":"12","author":"NJ Ashton","year":"2018","unstructured":"Ashton NJ, Scholl M, Heurling K, Gkanatsiou E, Portelius E, Hoglund K et al (2018) Update on biomarkers for amyloid pathology in Alzheimer's disease. Biomark Med 12:799\u2013812. https:\/\/doi.org\/10.2217\/bmm-2017-0433","journal-title":"Biomark Med"},{"key":"2195_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","volume":"71","author":"TG Beach","year":"2012","unstructured":"Beach TG, Monsell SE, Phillips LE, Kukull W (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005\u20132010. J Neuropathol Exp Neurol 71:266\u2013273. https:\/\/doi.org\/10.1097\/NEN.0b013e31824b211b","journal-title":"J Neuropathol Exp Neurol"},{"key":"2195_CR5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.dadm.2019.08.002","volume":"11","author":"AL Benedet","year":"2019","unstructured":"Benedet AL, Ashton NJ, Pascoal TA, Leuzy A, Mathotaarachchi S, Kang MS et al (2019) Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals. Alzheimers Dement (Amst) 11:679\u2013689. https:\/\/doi.org\/10.1016\/j.dadm.2019.08.002","journal-title":"Alzheimers Dement (Amst)"},{"key":"2195_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368:387\u2013403. https:\/\/doi.org\/10.1016\/S0140-6736(06)69113-7","journal-title":"Lancet"},{"key":"2195_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","volume":"112","author":"H Braak","year":"2006","unstructured":"Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389\u2013404. https:\/\/doi.org\/10.1007\/s00401-006-0127-z","journal-title":"Acta Neuropathol"},{"key":"2195_CR8","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/brain\/awaa054","volume":"143","author":"F de Wolf","year":"2020","unstructured":"de Wolf F, Ghanbari M, Licher S, McRae-McKee K, Gras L, Weverling GJ et al (2020) Plasma tau, neurofilament light chain and amyloid-beta levels and risk of dementia; a population-based cohort study. Brain 143:1220\u20131232. https:\/\/doi.org\/10.1093\/brain\/awaa054","journal-title":"Brain"},{"key":"2195_CR9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K et al (2014) Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13:614\u2013629. https:\/\/doi.org\/10.1016\/S1474-4422(14)70090-0","journal-title":"Lancet Neurol"},{"key":"2195_CR10","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U et al (2017) Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88:930\u2013937. https:\/\/doi.org\/10.1212\/WNL.0000000000003680","journal-title":"Neurology"},{"key":"2195_CR11","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1093\/brain\/awl279","volume":"129","author":"A Hye","year":"2006","unstructured":"Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL et al (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129:3042\u20133050. https:\/\/doi.org\/10.1093\/brain\/awl279","journal-title":"Brain"},{"issue":"799\u2013807","key":"2195_CR12","doi-asserted-by":"publisher","first-page":"e792","DOI":"10.1016\/j.jalz.2014.05.1749","volume":"10","author":"A Hye","year":"2014","unstructured":"Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R et al (2014) Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement 10(799\u2013807):e792. https:\/\/doi.org\/10.1016\/j.jalz.2014.05.1749","journal-title":"Alzheimers Dement"},{"key":"2195_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB et al (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement 14:535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"key":"2195_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS et al (2013) Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207\u2013216. https:\/\/doi.org\/10.1016\/S1474-4422(12)70291-0","journal-title":"Lancet Neurol"},{"key":"2195_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE et al (2020) Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med 26:379\u2013386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1","journal-title":"Nat Med"},{"key":"2195_CR16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL et al (2020) Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 19:422\u2013433. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5","journal-title":"Lancet Neurol"},{"key":"2195_CR17","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E et al (2019) Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry 24:1112\u20131134. https:\/\/doi.org\/10.1038\/s41380-018-0342-8","journal-title":"Mol Psychiatry"},{"key":"2195_CR18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K (2019) Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol 76:791\u2013799. https:\/\/doi.org\/10.1001\/jamaneurol.2019.0765","journal-title":"JAMA Neurol"},{"key":"2195_CR19","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","volume":"87","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E et al (2016) Plasma tau in Alzheimer disease. Neurology 87:1827\u20131835. https:\/\/doi.org\/10.1212\/WNL.0000000000003246","journal-title":"Neurology"},{"key":"2195_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:263\u2013269. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","journal-title":"Alzheimers Dement"},{"key":"2195_CR21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","volume":"136","author":"JL Molinuevo","year":"2018","unstructured":"Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J et al (2018) Current state of Alzheimer's fluid biomarkers. Acta Neuropathol 136:821\u2013853. https:\/\/doi.org\/10.1007\/s00401-018-1932-x","journal-title":"Acta Neuropathol"},{"key":"2195_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V et al (2018) High performance plasma amyloid-beta biomarkers for Alzheimer's disease. Nature 554:249\u2013254. https:\/\/doi.org\/10.1038\/nature25456","journal-title":"Nature"},{"key":"2195_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.1632","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K et al (2019) Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1632","journal-title":"JAMA Neurol"},{"key":"2195_CR24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamaneurol.2018.4666","volume":"76","author":"MP Pase","year":"2019","unstructured":"Pase MP, Beiser AS, Himali JJ, Satizabal CL, Aparicio HJ, DeCarli C et al (2019) Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes. JAMA Neurol 76:598\u2013606. https:\/\/doi.org\/10.1001\/jamaneurol.2018.4666","journal-title":"JAMA Neurol"},{"key":"2195_CR25","unstructured":"Patterson C (2018) World Alzheimer report 2018. The state of the art of dementia research: new frontiers. https:\/\/www.alzcouk\/research\/WorldAlzheimerReport2018pdf Accessed 20 May 2020"},{"key":"2195_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jalz.2008.10.004","volume":"5","author":"AE Roher","year":"2009","unstructured":"Roher AE, Esh CL, Kokjohn TA, Castano EM, Van Vickle GD, Kalback WM et al (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 5:18\u201329. https:\/\/doi.org\/10.1016\/j.jalz.2008.10.004","journal-title":"Alzheimers Dement"},{"issue":"1284\u20131298","key":"2195_CR27","doi-asserted-by":"publisher","first-page":"e1287","DOI":"10.1016\/j.neuron.2018.02.015","volume":"97","author":"C Sato","year":"2018","unstructured":"Sato C, Barthelemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J et al (2018) Tau kinetics in neurons and the human central nervous system. Neuron 97(1284\u20131298):e1287. https:\/\/doi.org\/10.1016\/j.neuron.2018.02.015","journal-title":"Neuron"},{"key":"2195_CR28","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA et al (2019) High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93:e1647\u2013e1659. https:\/\/doi.org\/10.1212\/WNL.0000000000008081","journal-title":"Neurology"},{"key":"2195_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.mcn.2018.12.001","volume":"97","author":"M Scholl","year":"2019","unstructured":"Scholl M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H et al (2019) Biomarkers for tau pathology. Mol Cell Neurosci 97:18\u201333. https:\/\/doi.org\/10.1016\/j.mcn.2018.12.001","journal-title":"Mol Cell Neurosci"},{"key":"2195_CR30","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jnen\/nlw026","volume":"75","author":"A Serrano-Pozo","year":"2016","unstructured":"Serrano-Pozo A, Qian J, Muzikansky A, Monsell SE, Montine TJ, Frosch MP et al (2016) Thal amyloid stages do not significantly impact the correlation between neuropathological change and cognition in the Alzheimer disease continuum. J Neuropathol Exp Neurol 75:516\u2013526. https:\/\/doi.org\/10.1093\/jnen\/nlw026","journal-title":"J Neuropathol Exp Neurol"},{"key":"2195_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jalz.2018.01.012","volume":"14","author":"CL Sutphen","year":"2018","unstructured":"Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM et al (2018) Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. Alzheimers Dement 14:869\u2013879. https:\/\/doi.org\/10.1016\/j.jalz.2018.01.012","journal-title":"Alzheimers Dement"},{"key":"2195_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L et al (2020) Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med 26:387\u2013397. https:\/\/doi.org\/10.1038\/s41591-020-0762-2","journal-title":"Nat Med"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-020-02195-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-020-02195-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-020-02195-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T23:25:58Z","timestamp":1627341958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-020-02195-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["2195"],"URL":"https:\/\/doi.org\/10.1007\/s00401-020-02195-x","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]},"assertion":[{"value":"4 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant or at advisory boards for Axon, Biogen, CogRx, Lilly, MagQu, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. The other authors declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}